Cargando…
In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells
Melanoma is an aggressive skin cancer. Increasing evidence has shown the role of β-adrenergic receptors in the pathogenesis of melanoma. Carvedilol is a widely used non-selective β-AR antagonist with potential anticancer activity. The purpose of the study was to estimate the influence of carvedilol...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265481/ https://www.ncbi.nlm.nih.gov/pubmed/37323921 http://dx.doi.org/10.1016/j.jsps.2023.05.020 |
_version_ | 1785058541717946368 |
---|---|
author | Wawszczyk, Joanna Wolan, Radosław Smolik, Sławomir Kapral, Małgorzata |
author_facet | Wawszczyk, Joanna Wolan, Radosław Smolik, Sławomir Kapral, Małgorzata |
author_sort | Wawszczyk, Joanna |
collection | PubMed |
description | Melanoma is an aggressive skin cancer. Increasing evidence has shown the role of β-adrenergic receptors in the pathogenesis of melanoma. Carvedilol is a widely used non-selective β-AR antagonist with potential anticancer activity. The purpose of the study was to estimate the influence of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of C32 and A2058 melanoma cells. Furthermore, this study also aimed to predict the probable interaction of carvedilol and sorafenib when administered together. Predictive study of the interaction of carvedilol and sorafenib was performed using the ChemDIS-Mixture system. Carvedilol and sorafenib alone and in combination showed a growth inhibitory effect on cells. The greatest synergistic antiproliferative effect on both cell lines was observed at Car 5 μM combined with Sor 5 μM. Analysis in silico identified diseases, proteins, and metabolic pathways that can be affected by the interaction of carvedilol and sorafenib. The results obtained demonstrated that carvedilol and sorafenib modulated the secretion of IL-8 by IL-1β-stimulated by melanoma cell lines but the use of a combination of both drugs did not intensify the effect. In summary, the results presented indicate that the combination of carvedilol and sorafenib may have a promising anticancer effect on melanoma cells. |
format | Online Article Text |
id | pubmed-10265481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-102654812023-06-15 In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells Wawszczyk, Joanna Wolan, Radosław Smolik, Sławomir Kapral, Małgorzata Saudi Pharm J Original Article Melanoma is an aggressive skin cancer. Increasing evidence has shown the role of β-adrenergic receptors in the pathogenesis of melanoma. Carvedilol is a widely used non-selective β-AR antagonist with potential anticancer activity. The purpose of the study was to estimate the influence of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of C32 and A2058 melanoma cells. Furthermore, this study also aimed to predict the probable interaction of carvedilol and sorafenib when administered together. Predictive study of the interaction of carvedilol and sorafenib was performed using the ChemDIS-Mixture system. Carvedilol and sorafenib alone and in combination showed a growth inhibitory effect on cells. The greatest synergistic antiproliferative effect on both cell lines was observed at Car 5 μM combined with Sor 5 μM. Analysis in silico identified diseases, proteins, and metabolic pathways that can be affected by the interaction of carvedilol and sorafenib. The results obtained demonstrated that carvedilol and sorafenib modulated the secretion of IL-8 by IL-1β-stimulated by melanoma cell lines but the use of a combination of both drugs did not intensify the effect. In summary, the results presented indicate that the combination of carvedilol and sorafenib may have a promising anticancer effect on melanoma cells. Elsevier 2023-07 2023-05-26 /pmc/articles/PMC10265481/ /pubmed/37323921 http://dx.doi.org/10.1016/j.jsps.2023.05.020 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Wawszczyk, Joanna Wolan, Radosław Smolik, Sławomir Kapral, Małgorzata In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells |
title | In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells |
title_full | In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells |
title_fullStr | In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells |
title_full_unstemmed | In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells |
title_short | In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells |
title_sort | in vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265481/ https://www.ncbi.nlm.nih.gov/pubmed/37323921 http://dx.doi.org/10.1016/j.jsps.2023.05.020 |
work_keys_str_mv | AT wawszczykjoanna invitroandinsilicostudyontheeffectofcarvedilolandsorafenibaloneandincombinationonthegrowthandinflammatoryresponseofmelanomacells AT wolanradosław invitroandinsilicostudyontheeffectofcarvedilolandsorafenibaloneandincombinationonthegrowthandinflammatoryresponseofmelanomacells AT smoliksławomir invitroandinsilicostudyontheeffectofcarvedilolandsorafenibaloneandincombinationonthegrowthandinflammatoryresponseofmelanomacells AT kapralmałgorzata invitroandinsilicostudyontheeffectofcarvedilolandsorafenibaloneandincombinationonthegrowthandinflammatoryresponseofmelanomacells |